DOCSLIB.ORG

Novartis Group Annual Report 2010 Corporate Governance Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novartis Group Annual Report 2010 Corporate Governance Report 0 1 0 2 T R O P E R L A U N N ANNUAL REPORT 2010 A ANNUAL REPORT 2010 N O VA R T I S G R O U P A N N UA L R E P O R T 2 0 1 0 OUR MISSION We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. We also want to provide a shareholder return that refl ects outstanding performance and to adequately reward those who invest ideas and work in our company. 4 | GROUP REVIEW 19 | HEALTHCARE PORTFOLIO 57 | CORPORATE CITIZENSHIP 85 | CORPORATE GOVERNANCE 111 | COMPENSATION REPORT 131 | FINANCIAL REPORT 1 2 NO VA R T I S G R O U P A NN U A L R E P O R T 2 0 1 0 CONTENTS GROUP REVIEW Financial Highlights 4 News in 2010 5 Letter from Daniel Vasella 7 Interview with Joseph Jimenez 15 HEALTHCARE PORTFOLIO Contents 19 Pharmaceuticals 23 Novartis Institutes for BioMedical Research 35 Vaccines and Diagnostics 39 Sandoz 45 Consumer Health 51 CORPORATE CITIZENSHIP Contents 57 Commitment to Patients 61 Commitment to People and Communities 67 Commitment to the Environment 73 Commitment to Ethical Business Conduct 78 Independent Assurance Report 83 CORPORATE GOVERNANCE Contents 85 Our Board of Directors 90 Our Management 101 COMPENSATION REPORT Contents 111 Compensation Report 112 NOVARTIS GROUP FINANCIAL REPORT Contents 131 Operating and Financial Review 134 Equity Strategy 177 Novartis Group Consolidated Financial Statements 180 Financial Statements of Novartis AG 252 Annual Report Photography 268 Key Dates 2011, Contact Information 270 and Forward-Looking Statements 4 | GROUP REVIEW 19 | HEALTHCARE PORTFOLIO 57 | CORPORATE CITIZENSHIP 85 | CORPORATE GOVERNANCE 111 | COMPENSATION REPORT 131 | FINANCIAL REPORT 3 GROUP REVIEW Novartis provides healthcare solutions that address the evolving needs of patients and societies worldwide. We offer a portfolio focused on broad areas of healthcare to best meet these needs: innovative prescription medicines, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, and consumer health products. FINANCIAL HIGHLIGHTS KEY FIGURES NET SALES, OPERATING INCOME, NET INCOME, CORE OPERATING (In USD millions, unless indicated otherwise) INCOME AND CORE NET INCOME 4 (Index: 2005 = 100%) 2010 2009 200 Net sales 50 624 44 267 Operating income 11 526 9 982 175 Return on net sales (%) 22.8 22.5 Net income 9 969 8 454 150 Basic earnings per share 1 (USD) 4.28 3.70 Core 2 125 Operating income 14 006 11 437 Return on core net sales (%) 27.7 25.8 100 Net income 12 029 10 267 2005 2006 2007 2008 2009 2010 Basic earnings per share 1 (USD) 5.15 4.50 Research & Development 8 080 7 287 Net sales As a % of net sales 16.0 16.5 Operating income Number of associates (FTE) 3 119 418 99 834 Net income Return on average equity (%) 15.7 15.7 Core operating income Free cash flow 7 860 5 505 Core net income SHARE INFORMATION 2010 NET SALES BY REGION (% and in USD millions) 2010 2009 Share price at year-end (CHF) 54.95 56.50 United States 31 15 863 ADS price at year-end (USD) 58.95 54.43 Europe 37 18 558 Dividend 5 (CHF) 2.20 2.10 Pay-out ratio 6 55 53 Asia/Africa/Australasia 18 9 416 Canada and Latin America 9 4 361 Alcon, Inc. 7 5 2 426 Total 50 624 1 2010 average number of shares outstanding: 2 285.7 million (2009: 2 267.9 million) 4 To ease comparability, all figures in this chart for the years 2005 to 2007 exclude the Consumer 2 Core results for operating income, net income, earnings per share (EPS) and R&D eliminate the Health Divison Nutrition operations divested in 2007 impact of acquisition-related factors and other significant exceptional items. These adjustments 5 Dividend payment for 2010: proposal to 2011 Annual General Meeting are explained in detail starting on page 143. 6 Pay-out ratio is calculated based on net income attributable to shareholders of Novartis AG 3 Full-time equivalent positions at year-end, including 16 700 Alcon associates in 2010 7 Regional data for Alcon, Inc. is not available 4 NO VA R T I S G R O U P A NN U A L R E P O R T 2 0 1 0 NEWS IN 2010 PERFORMANCE Recently launched products drive strong top-line growth across broad healthcare portfolio. Net sales rise 14% (+14% in constant currencies) to USD 50.6 billion driven by strong growth in all businesses, including USD 2.4 billion from consolidation of Alcon. Operating income advances 15% to USD 11.5 billion on business expansion and productivity improvements. Core operating income rises 22% to USD 14.0 billion. Net income up 18% and core net income up 17% to USD 10.0 billion and USD 12.0 billion, respectively. PRODUCTS Products launched since 2007 account for 21% of net sales, as more than 13 major pharma- ceutical regulatory approvals in 2010 in the US, Europe and Japan continue to rejuvenate the portfolio. Approvals include Gilenya (multiple sclerosis) in the US, new indications for Lucentis (treatment of diabetic macular edema) in the EU and also for Tasigna (newly diagnosed CML) in the US, EU and Japan. Other key approvals include new vaccine Menveo (meningococcal disease) in the US and EU as well as US approval for generic enoxaparin. PIPELINE Industry-leading pharmaceutical pipeline with 147 projects in development and 16 major submissions in 2010 in the US, EU and Japan including ACZ885 in gout in the EU, Lucentis in retinal vein occlusion in the EU, SOM230 in Cushing’s disease in the EU, and Afi nitor in advanced neuroendocrine tumors in the EU and the US. Early pipeline in Vaccines progresses rapidly as Bexsero, a breakthrough meningococcal B vaccine, is fi led for EU approval. RESEARCH Signifi cant investment focusing on areas of greatest patient need and high scientifi c promise at the Novartis Institutes for BioMedical Research aims to discover novel therapies. Biologics account for an increasing proportion of the exploratory pipeline. PORTFOLIO Strengthening our focused portfolio, Novartis completes the purchase from Nestlé S.A. of majority control of Alcon, Inc., the world’s leading eye care company and reaches merger agreement with Alcon, Inc., to acquire all outstanding publicly held shares. Sandoz acquires Oriel Therapeutics, gaining rights to a portfolio of generic respiratory products and in Vaccines and Diagnostics the acquisition of a majority holding in Zhejiang Tianyuan nears completion. CORPORATE CITIZENSHIP Engaging with society to improve healthcare is integral to how Novartis operates. Access- to-medicine programs for those in need reach 85 million patients in 2010 and, together with our R&D institutes for diseases in developing countries, totaled USD 1.5 billion or 3% of net sales. DIVIDEND 14th consecutive dividend increase with 5% raise proposed for 2010 to CHF 2.20 per share (2009: CHF 2.10 per share), a dividend yield of 4.0%. LEADERSHIP Group leadership strengthened as Joseph Jimenez is promoted to CEO with Daniel Vasella continuing as Chairman of the Board of Directors. David Epstein replaces Mr. Jimenez as Division Head, Pharmaceuticals, and Jonathan Symonds succeeds Raymund Breu as Chief Financial Offi cer. 4 | GROUP REVIEW 19 | HEALTHCARE PORTFOLIO 57 | CORPORATE CITIZENSHIP 85 | CORPORATE GOVERNANCE 111 | COMPENSATION REPORT 131 | FINANCIAL REPORT 5 Financial Highlights News in 2010 6 NO VA R T I S G R O U P A NN U A L R E P O R T 2 0 1 0 DEAR SHAREHOLDER Let me summarize the results achieved in the last year: – Net sales grew 14% (+14% in constant currencies) to USD 50.6 billion. I am pleased to report record results for 2010, both in sales and in profits. – Operating income rose by 15% (+17% in constant currencies) to USD 11.5 billion. The past year was shaped by repercussions from the global financial crisis and consid- – Net income climbed 18% (+20% in con- erable currency turbulence. Despite these stant currencies) to USD 10.0 billion, faster difficult conditions, Novartis was very than operating income. successful. Our well-balanced business portfolio and long-term strategy focused – Free cash flow before dividends reached on innovation once more have proved to USD 12.3 billion. be robust and appropriate for the future. Daniel Vasella, M.D. The ability to repeatedly launch new and – Alcon was fully consolidated from better products, and thus establish market August 25 when we completed the pur- positions, is decisive for the sustainability chase of an additional 52% stake in the of our success. We demonstrated both of eye care leader. From that date, Alcon these core competencies last year. New net sales totaled USD 2.4 billion; oper- and recently launched products were a key ating income amounted to USD 323 mil- growth driver in 2010 and hold more prom- lion; and core operating income was ise for the future. Joe Jimenez, our new USD 852 million. CEO since February 2010, has successfully continued this strategy and launched new The PharmaceuticalS DiviSion (USD 30.6 initiatives to improve productivity. His billion, +6% in constant currencies) nomination has proven to be right both achieved strong volume growth of eight in terms of timing and in terms of the divi- percentage points. Sales of recently sion of labor between the Chairman and launched products were USD 6.6 billion the CEO. accounting for 21% of the division’s sales, a significant increase from 16% the pre- In addition, since August 2010, Novartis vious year.
Load more

Recommended publications
  • Novartis / Chiron Regulation (Ec)
    EN Case No COMP/M.4049 - NOVARTIS / CHIRON Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 06/02/2006 In electronic form on the EUR-Lex website under document number 32006M4049 Office for Official Publications of the European Communities L-2985 Luxembourg COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 06-02-2006 SG-Greffe (2006) D/200529 In the published version of this decision, some information has been omitted pursuant to Article 17(2) of Council Regulation (EC) No 139/2004 concerning non-disclosure of business secrets and PUBLIC VERSION other confidential information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a MERGER PROCEDURE general description. ARTICLE 6(1)(b) DECISION To the notifying party Dear Madam/Sir, Subject: Case No. COMP/M.4049 – Novartis / Chiron Notification of 23/12/2005 pursuant to Article 4 of Council Regulation No 139/20041 (“Merger Regulation”) 1. On 23/12/2005, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 by which the undertaking Novartis AG (“Novartis”, Switzerland) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Chiron Corporation (“Chiron”, United States) by way of purchase of shares. 2. After examination of the notification, the Commission has concluded that the notified operation constitutes a concentration that falls within the scope of the Merger Regulation and does not raise serious doubts as to its compatibility with the common market and the EEA Agreement.
    [Show full text]
  • Documenting the Biotechnology Industry in the San Francisco Bay Area
    UC San Diego Reports and Studies Title Documenting the Biotechnology Industry in the San Francisco Bay Area Permalink https://escholarship.org/uc/item/1m24k447 Author Chandler, Robin L. Publication Date 1997 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Documenting the Biotechnology Industry In the San Francisco Bay Area Robin L. Chandler Head, Archives and Special Collections UCSF Library and Center for Knowledge Management 1997 1 Table of Contents Project Goals……………………………………………………………………….p. 3 Participants Interviewed………………………………………………………….p. 4 I. Documenting Biotechnology in the San Francisco Bay Area……………..p. 5 The Emergence of An Industry Developments at the University of California since the mid-1970s Developments in Biotech Companies since mid-1970s Collaborations between Universities and Biotech Companies University Training Programs Preparing Students for Careers in the Biotechnology Industry II. Appraisal Guidelines for Records Generated by Scientists in the University and the Biotechnology Industry………………………. p. 33 Why Preserve the Records of Biotechnology? Research Records to Preserve Records Management at the University of California Records Keeping at Biotech Companies III. Collecting and Preserving Records in Biotechnology…………………….p. 48 Potential Users of Biotechnology Archives Approaches to Documenting the Field of Biotechnology Project Recommendations 2 Project Goals The University of California, San Francisco (UCSF) Library & Center for Knowledge Management and the Bancroft Library at the University of California, Berkeley (UCB) are collaborating in a year-long project beginning in December 1996 to document the impact of biotechnology in the Bay Area. The collaborative effort is focused upon the development of an archival collecting model for the field of biotechnology to acquire original papers, manuscripts and records from selected individuals, organizations and corporations as well as coordinating with the effort to capture oral history interviews with many biotechnology pioneers.
    [Show full text]
  • Regional Oral History Office University of California the Bancroft Library Berkeley, California
    Regional Oral History Office University of California The Bancroft Library Berkeley, California Program in Bioscience and Biotechnology Studies RONALD E. CAPE, M.B.A., Ph. D. BIOTECH PIONEER AND CO-FOUNDER OF CETUS Interviews Conducted by Sally Smith Hughes in 2003 Copyright © 2006 by The Regents of the University of California Since 1954 the Regional Oral History Office has been interviewing leading participants in or well-placed witnesses to major events in the development of northern California, the West, and the nation. Oral history is a method of collecting historical information through tape-recorded interviews between a narrator with firsthand knowledge of historically significant events and a well-informed interviewer, with the goal of preserving substantive additions to the historical record. The tape recording is transcribed, lightly edited for continuity and clarity, and reviewed by the interviewee. The corrected manuscript is indexed, bound with photographs and illustrative materials, and placed in The Bancroft Library at the University of California, Berkeley, and in other research collections for scholarly use. Because it is primary material, oral history is not intended to present the final, verified, or complete narrative of events. It is a spoken account, offered by the interviewee in response to questioning, and as such it is reflective, partisan, deeply involved, and irreplaceable. ************************************ All uses of this manuscript are covered by legal agreements between The Regents of the University of California and Ronald Cape, dated December 18, 2003. The manuscript is thereby made available for research purposes. All literary rights in the manuscript, including the right to publish, are reserved to The Bancroft Library of the University of California, Berkeley.
    [Show full text]
  • Richard Gregory, Et Al. V. Chiron Corporation, Et Al. 04-CV-04293-Request for Judicial Notice in Support of Chiron Corporation&
    EXHIBIT F Chiron News Page 1 of 9 Lc Chiron Reports 2003 Second -Quarter Pro-Forma Income of 35 Cents Per Share 17 Percent Increase in Revenues Over 200 2 EMERYVILLE, Calif., July 23 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq : CHIR) today reported pro-forma income from continuing operations of $67 million, or $0 .35 per share, for the second quarter of 2003, compared to $56 million, or $0.29 per share, for the second quarter of 2002 . (Chiron management uses pro-forma financial statements to gain an understanding of the company's operating performance on a comparative basis . Pro-forma results exclude special items relating to certain acquisitions and revenues, which may not be relevant to gaining an understanding of the company's trends or potential future performance . Please refer to the attached tables at the end of this document for more detail on these items and a reconciliation to GAAP financial statements .) On a GAAP basis, Chiron's income from continuing operations was $61 million, or $0 .32 per share, for the second quarter of 2003, compared to $50 million, or $0 .26 per share, for the second quarter of 2002 . (All references to per-share amounts are per diluted share .) Foreign exchange rates, on a pro-forma basis, resulted in a $0 .01 increase in earnings per share . "Chiron made several important advances that demonstrate our momentum as a global biopharmaceutical company and that will help drive growth from the immediate to the long term, increasing shareholder value," said Howard Pion, Chiron's president and CEO . "Prominent among these was our acquisition of PowderJect, which makes us the second-largest flu vaccines manufacturer worldwide and adds a U .S.
    [Show full text]
  • Spare the Air Employer Program Members
    Spare the Air Employer Program Members 511 Affymetrix Inc. 1000 Journals Project Agilent Technologies ‐ Sonoma County 3Com Corporation Public Affairs 511 Contra Costa Agnews Developmental Center 511 Regional Rideshare Program AHDD Architecture 7‐Flags Car Wash Air Products and Chemicals, Inc. A&D Christopher Ranch Air Systems Inc. A9.com Akeena Solar AB & I Akira ABA Staffing, Inc. Akraya Inc. ABB Systems Control Alameda Co. Health Care for the Homeless Abgenix, Inc. Program ABM Industries, Inc Alameda County Waste Management Auth. Above Telecommunications, Inc. Alameda Free Library Absolute Center Alameda Hospital AC Transit Alameda Unified School District Academy of Art University Alder & Colvin Academy of Chinese Culture & Health Alexa Internet Acclaim Print & Copy Centers Allergy Medical Group Of S F A Accolo Alliance Credit Union Accretive Solutions Alliance Occupational Medicine ACF Components Allied Waste Services/Republic Services Acologix Inc. Allison & Partners ACRT, Inc Alta Bates/Summit Medical Center ACS State & Local Solutions Alter Eco Act Now Alter Eco Americas Acterra ALTRANS TMA, Inc Actify, Inc. Alum Rock Library Adaptive Planning Alza Corporation Addis Creson American Century Investment Adina for Life, Inc. American International (Group) Companies Adler & Colvin American Lithographers ADP ‐ Automatic Data Processing American Lung Association Advance Design Consultants, Inc. American Musical Theatre of San Jose Advance Health Center American President Lines Ltd Advance Orthopaedics Amgen, Inc Advanced Fibre Communications Amtrak Advanced Hyperbaric Recovery of Marin Amy’s Kitchen Advanced Micro Devices, Inc. Ananda Skin Spa Advantage Sales & Marketing Anderson Zeigler Disharoon Gallagher & Advent Software, Inc Gray Aerofund Financial Svcs.,Inc. Anixter Inc. Affordable Housing Associates Anomaly Design Affymax Research Institute Anritsu Corporation Anshen + Allen, Architects BabyCenter.com Antenna Group Inc BACE Geotechnical Anza Library BackFlip APEX Wellness Bacon's Applied Biosystems BAE Systems Applied Materials, Inc.
    [Show full text]
  • Growth and Urban Redevelopment in Emeryville
    Growth and Urban Redevelopment in Emeryville East Bay Alliance for a Sustainable Economy Center for Labor Research and Education University of California, Berkeley A Publication of the California Partnership for Working Families May 2003 Growth and Urban Redevelopment in Emeryville East Bay Alliance for a Sustainable Economy Center for Labor Research and Education University of California, Berkeley Howard Greenwich Elizabeth Hinckle May 2003 A Publication of the California Partnership for Working Families East Bay Alliance for a Sustainable Economy, Oakland, CA Center on Policy Initiatives, San Diego, CA Los Angeles Alliance for a New Economy, CA Working Partnerships USA, San Jose, CA BEHIND THE BOOMTOWN ACKNOWLEDGEMENTS AND CREDITS This report was prepared by EBASE with the generous support of many individuals and organizations. We are indebted to the community members, workers, city representatives, and businesses of Emeryville for their time and insights into the transfor- mation of their city. We would like to thank: community members Angel Norris, Gladys Vance, Jim Martin, Barbara MacQuiddy, Gisele Wolf, Mary McGruder, Russell Moran, Bridget Burch, and Deloris Prince; store managers Al Kruger, Renee Conse, Sam Combs, Carlos Torres, and Chuck Pacioni; developers Pat Cashman, Shi-Tso Chen, Eric Hohmann, Glenn Isaacson, and Steven Meckfessel; businesspersons Bob Cantor and Jay Grover; current and former city staff members Ignacio Dayrit, Ron Gerber, Ellen Whitton, Pauline Marx, Karan Reid, Autumn Buss, Patrick O’Keeffe, Jeannie Wong, Wendy Silvani and Rebecca Atkinson; former City Councilmembers and Planning Commissioners Stu Flashman, Andy Getz and Greg Harper; current City Councilmembers Ruth Atkin and Nora Davis; and from the Emery Unified School District, State Administrator Henry Der and Advisory Board President Forrest Gee.
    [Show full text]
  • Annual Report 1998 Expertise with Responsibility
    Annual Report 1998 Expertise with Responsibility Bayer is a diversified, international chemicals and health care group. We offer our customers a wide variety of products and services in areas ranging from pharmaceuticals and crop protection to plastics, specialty chemicals and imaging technologies. Bayer is research-based and aims for technological leadership in its core activities. Our goals are to steadily increase corporate value and generate a high value added for the benefit of our stockholders, our employees and the community in every country in which we operate. We believe that our technical and commercial expertise involves a responsibility to work for the common good and contribute to sustainable development. Bayer: Success through Expertise with Responsibility. Bayer Key Data Bayer Group 1998 1997 Change in % Sales DM million 54,884 55,005 – 0.2 Operating result DM million 6,151 6,018 + 2.2 Income before income taxes DM million 5,336 5,108 + 4.5 Net income DM million 3,157 2,941 + 7.3 Gross cash flow DM million 6,602 6,480 + 1.9 Stockholders’ equity DM million 24,991 23,923 + 4.5 Total assets DM million 57,216 54,170 + 5.6 Capital expenditures DM million 5,165 4,559 + 13.3 Employees at year end 145,100 144,600 + 0.3 Personnel expenses DM million 15,854 15,442 + 2.7 Research and development expenses DM million 3,920 3,878 + 1.1 Bayer AG 1998 1997 Change in % Total dividend payment DM million 1,461 1,388 + 5.3 Dividend per share DM 2.00 1.90 + 5.3 Tax credit DM 0.65 0.81 - 19.8 Published by Bayer AG, 51368 Leverkusen, This complete version of the Annual Report Germany is published in English and German.
    [Show full text]
  • Regular Meeting
    PLEASE POST INCORPORATED 1896 1333 Park Avenue. Emeryville, CA 94608-3517 t (510) 596-4300 | f (510) 596-4389 Chair John Bauters Member Dianne Martinez BUDGET AND GOVERNANCE COMMITTEE Regular Meeting Actions taken by Advisory Bodies are not official actions of the City TELECONFERENCE Council, but must be ratified at a 1) Zoom Meeting Information: regular City Council meeting. https://emeryville-org.zoom.us/j/94164375340?pwd=SzVkZVlHVFRPb1RDMnpEZ1RNTTl6QT09 Password 259373. All writings that are public records 2) Audio Only: Call in to 669-900-6833, Meeting ID 941 6437 5340, Password 259373. and relate to an agenda item which December 10, 2020 – 11:00 AM are distributed to a majority of the legislative body less than 72 hours prior to the meeting noticed will be AGENDA made available via email by request the Committee Secretary. 1. Call to Order In compliance with the Americans 2. Roll Call with Disabilities Act, a person requiring an accommodation, 3. Public Comment auxiliary aid, or service to participate in this meeting should contact the 3.1 Submit an Online Speaker Card at www.emeryville.org/advisorybodies Committee Secretary as far in advance as possible, but no later 4. Approval of Meeting Action Minutes than 72 hours prior to the scheduled event. The best effort to fulfill the 4.1 October 8, 2020 Regular Meeting Minutes request will be made. Pursuant to California Governor Gavin 5. Information Items Newsom’s Executive Order N-29- st 20, the City is authorized to hold 5.1 Fiscal Year 2020-21 1 Quarter Financial Update public meetings via teleconferenc- ing and to make public meetings 6.
    [Show full text]
  • Commercializing the New Biology: a Tribute to Ronald E. Cape
    SIMB MolecularPioneering NewsResearch CEO News magazine of the Society for Industrial BiochemistMicrobiologyUniversity and Biotechnology DNAV N October/November/DecemberPolymerase 2019 .69 .4 • www.simbhq.orgBusinessScientific Entrepreneurial Industry Corporation FounderCommercializing Interferon Constellation Genethe New Biology: ApplicationChairman A Tribute to Patent Pharmaceutical PCR Recombinant BreakthroughDiagnostic Cloning RonaldVenture E. Cape Leadership Cetus Biotechnology2020 Election PresidentInterleukinfor Board of DirectorsBusinessman Call for SIMB Award 4 . .69 2019 October/November/December N V Nominations Journal of Industrial Microbiology & Biotechnology Impact Factor 2.993 The Journal of Industrial Microbiology and Biotechnology is an international journal which publishes papers in all areas of applied microbiology, e.g., biotechnology, fermentation and cell culture, biocatalysis, environmental microbiology, natural products discovery and biosynthesis, metabolic engineering, genomics, bioinformatics, food microbiology. Editor-in-Chief • Ramon Gonzalez, Rice University, Houston, TX, USA Special Issue Natural Product Discovery and Editors Development in the Genomic Era; Mar. 2019 • S. Bagley, Michigan Tech, Houghton, MI, USA • R. H. Baltz, CognoGen Biotech. Consult., Sarasota, FL, USA • T. W. Jeffries, University of Wisconsin, Madison, WI, USA • T. D. Leathers, USDA ARS, Peoria, IL, USA • M. J. López López, University of Almeria, Almeria, Spain • C. D. Maranas, Pennsylvania State Univ., Univ. Park, PA, USA • S. Park, UNIST, Ulsan, Korea • J. L. Revuelta, University of Salamanca, Salamanca, Spain • B. Shen, Scripps Research Institute, Jupiter, FL, USA • D. K. Solaiman, USDA ARS, Wyndmoor, PA, USA • Y. Tang, University of California, Los Angeles, CA, USA • E. J. Vandamme, Ghent University, Ghent, Belgium • J. Yang, Amgen Inc., Oak Park, CA, USA • H. Zhao, University of Illinois, Urbana, IL, USA 5 Most Cited Articles of JIMB in 2018: Authors Title Year Cites Katz, Leonard; Baltz, Richard H.
    [Show full text]
  • Caring and Curing
    Caring and Curing Annual Report 2002 Novartis www.novartis.com Annual Report 2002 …molecules for medicines… Martin Klumpp, PhD, Lukas Leder, PhD, and Aline Tirat, Novartis Lead Discovery Center, Basel, Switzerland ...writing in sand... Sarvodaya Pre-School, Paluchera, Sri Lanka Contents Financial Highlights2 News in 20023 Letter from Daniel Vasella5 Amazing Patient Stories9 Division and Product Review Pharmaceuticals14 Joining Forces in the Quest for Cures22 Consumer Health29 Corporate Citizenship37 Animal Welfare46 Health, Safety and Environment49 Human Resources60 Corporate Governance Corporate Governance67 Board of Directors79 Executive Committee82 Business Unit Heads84 Financial Report Operating and Financial Review87 Equity Strategy and Share Information98 Group Consolidated Financial Statements and Notes104 Principal Companies138 Reconciliation to US GAAP140 Financial Statements of Novartis AG151 Due Dates for Reporting and Contacts157 Front cover: Svenja, a young eczema patient during an examination at the Center for Dermatology, University of Frankfurt am Main, Germany. Back cover: Svenja with her brother, Jan Patrick in the pediatric ward. Novartis Group 1 Financial Highlights Sales CHF millions Free cash flow2 CHF millions 2002 32 412 2002 4 463 2001 31 643 2001 4 073 20001 29 112 20001 3 254 Operating income CHF millions Research and development CHF millions 2002 7 887 2002 4 339 2001 7 277 2001 4 189 20001 6 727 20001 4 011 Net income CHF millions Employees at year end 2002 7 313 2002 72 877 2001 7 024 2001 71 116 20001 6
    [Show full text]
  • View the Gala Program
    Global Citizen Award presented to Professor Klaus Schwab September 23, 2010 The Plaza • New York International Advisory Board Lt Gen Brent Scowcroft, USAF (Ret.), Chairman National Security Advisor to Presidents Gerald Ford and George H. W. Bush Senator Chuck Hagel Mr. Thomas H. Glocer The Rt. Hon. Lord Robertson of Chairman, Atlantic Council of the CEO, Thompson Reuters Port Ellen United States Mr. Francisco Gonzalez Former Secretary General of NATO Mr. Frederick Kempe Chairman & CEO, BBVA Ms. Güler Sabanci President & CEO, Atlantic Council Dr. James Goodnight Chairman & Managing Director, Members: Chief Executive Officer, SAS Haci Ömer Sabanci Holding A.S. Dr. Josef Ackermann Mr. Muhtar Kent Mr. Stephen A. Schwarzman Chairman of the Management Board Chairman & CEO, Chairman, CEO & Co-Founder, & the Group Executive Committee, The Coca-Cola Company The Blackstone Group Deutsche Bank AG President Aleksander Kwasniewski Sir Martin Sorrell H.E. Shaukat Aziz Former President of Poland Group Chief Executive, WPP Group PLC Former Prime Minister of Pakistan Mr. Jean Lemierre President Jose Maria Aznar Former President, The European Bank Mr. Robert J. Stevens Former Prime Minister of Spain for Reconstruction and Development Chairman, President & CEO, Lockheed Martin Dr. Zbigniew Brzezinski Mr. Alexey A. Mordashov National Security Advisor to President CEO, Severstal Mr. Sergey A. Taruta Jimmy Carter Chairman of the Board, Mr. Bob Moritz Industrial Union of Donbass Mr. Victor L. L. Chu U.S. Chairman & Senior Partner, Chairman, First Eastern Investment PricewaterhouseCoopers Dr. Gunter Thielen Group Chairman of the Supervisory Board, Mr. Rupert Murdoch Bertelsmann AG Mr. Richard Edelman Chairman & CEO, News Corporation President & CEO, Edelman Mr.
    [Show full text]
  • ANNUAL REPORT 2012 Contents OUR Mission
    ANNUAL REPORT 2012 cONTENTs OUR missiON GROUP REviEW Financial Highlights 2 We want to discover, develop and News in 2012 3 successfully market innovative Letter from Daniel vasella 5 products to prevent and cure interview with Joseph Jimenez 11 diseases, to ease suffering and HEALTHcAREPORTFOLiO contents 17 to enhance the quality of life. Pharmaceuticals 21 Novartis institutes for Biomedical Research 33 We also want to provide a Alcon 37 shareholder return that reflects sandoz 47 outstanding performance and vaccines and Diagnostics 53 to adequately reward those consumer Health 59 who invest ideas and work in cORPORATE REsPONsiBiLiTy contents 65 our company. Expanding Access to Healthcare 67 Doing Business Responsibly 77 independent Assurance Report 85 cORPORATE GOvERNANcE contents 87 Our Board of Directors 96 Our management 110 cOmPENsATiON REPORT contents 121 compensation Report 122 NOvARTis GROUP FiNANciAL REPORT contents 147 Financial Highlights 2012 148 Key Financial Developments 149 Operating and Financial Review 150 shareinformation 168 summary of Key Financial Data 188 Novartis Group consolidated Financial statements 190 Financial statements of Novartis AG 258 Annual Report Photography and Films 278 Key Dates 2013, contact information 280 and Forward-Looking statements 1 GROUP REviEW Novartis provides healthcare solutions that address the evolving needs of patients and societies worldwide. Our portfolio focuses on broad areas of healthcare: pharmaceuticals, eye care, generics, vaccines, consumer-based OTc and animal health. FiNaNcial
    [Show full text]